Eli Lilly and Company has broken ground on a new $1-billion biotech manufacturing campus in Raheen, County Limerick, Ireland, which will be Lilly’s most advanced manufacturing site for existing monoclonal antibodies. This site will produce existing products as well as the company’s pipeline of clinical products by 2026. The campus is expected to employ around 300 people across various disciplines. Recruitment will begin in early 2023. Additionally, the company plans to invest $500 million in Limerick to create a new biologics active ingredients site. 

The new $1.5-billion combined investment in Ireland is in addition to an $1-billion investment that the company announced in January 2022, for a new injectable products and devices manufacturing site in Concord, North Carolina.  

Source: Eli Lilly and Company